Kaira K, Mouri A, Kato S, et al. - Among patients with stage III non-small cell lung cancer with a performance status of 2 and/or are older, this phase II study aims to evaluate the impact of daily carboplatin plus radiotherapy followed by durvalumab. Patients are given daily, intravenous, low-dose carboplatin (30 mg/m² in a 30-min infusion) 1 hour prior to radiotherapy for the first 20 fractions. All patients received radiotherapy comprising 60 Gy administered as 30 fractions over 6 weeks. For up to 12 months post-chemoradiotherapy, durvalumab at a dose of 10 mg/kg/body is intravenously delivered every 2 weeks. The findings of this study will demonstrate that durvalumab affords an efficacious and tolerable choice for maintenance therapy following daily carboplatin plus radiotherapy. Experts have anticipated that the findings of an exploratory study will verify if the outcomes of this regimen could be predicted by the integrated evaluation of T-cell markers, programmed death receptor 1-ligand expression, and tumor mutation burden.